Tetra Bio-Pharma

134 articles with Tetra Bio-Pharma

• Tetra Bio-Pharma Announces Listing to OTCPink Market

  2/10/2023

  Tetra Bio-Pharma Inc. announced that its common shares began trading on the OTC Markets Group's OTCPink Market in the United States under the symbol "TBPMF" effective at the opening of trading on Friday, February 10, 2023 and will continue to trade on the Toronto Stock Exchange under the ticker symbol "TBP".

• Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

  12/6/2022

  Tetra Bio-Pharma Inc. announced today significant results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), Sepsis, and COVID-19 through PREPAiRE.

• Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003

  11/29/2022

  Tetra Bio-Pharma Inc. today announced the filing of three patent applications for its novel therapeutic, ARDS-003.

• Tetra Bio-Pharma Provides Update on Its REDUVO New Drug Submission

  11/18/2022

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with a regulatory status update on the REDUVO™ New Drug Submission (NDS). 

• Tetra and Prepaire Jointly Apply to BARDA for Funding

  10/11/2022

  Companies jointly submitted a $750,000 USD application to BARDA to use Prepaire™ Shield discovery platform to assess repurposed drugs combined with onternabez as Chemical Threat Medical Countermeasures.

• Alpha Blue Ocean (“ABO”) Announces a CAD 10M Financing Arrangement with Tetra Bio-Pharma (“TBP” or the “Company”)

  9/14/2022

  CAD 10M financing arrangement with Tetra Bio-Pharma (TBP).

• Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean

  9/8/2022

  Tetra Bio-Pharma Inc. announced that the Company has revised the terms of its previously announced financing arrangement with Global Corporate Finance Opportunities 16, an investment vehicle advised by Alpha Blue Ocean, and has closed the first tranche of the Financing on such revised terms, the whole pursuant to the terms of an amended and restated subscription agreement dated September 2, 2022.

• Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients

  9/6/2022

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today they signed an agreement with Cellvera Global Holdings LLC ("Cellvera"), for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.   

• Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean

  8/12/2022

  Tetra Bio-Pharma Inc. announced that it has entered into a subscription agreement with Global Corporate Finance Opportunities 16, an investment vehicle advised by Alpha Blue Ocean Inc., whereby Tetra has agreed to issue to the Investor senior unsecured convertible debentures in the aggregate principal amount of up to $6,000,000, and warrants to purchase common shares in the capital of the Company.

• Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

  8/10/2022

  Tetra Bio-Pharma Inc., a leader in cannabinoid-derived drug discovery and development announced new positive preclinical results from live SARS-CoV-2 virus infection studies as well as a septic lung model, carried out by independent researchers.

• Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug

  7/12/2022

  Akanda Corp. and Tetra Bio-Pharma today jointly announced that Akanda will supply Tetra with pharmaceutical grade cannabis flower in a microdose cap form, for use in a Storz & Bickel Mighty Medic Vaporizer for global commercialization of Tetra’s QIXLEEFTM and related products.

• Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update

  6/6/2022

  Tetra Bio-Pharma Inc. announces the launch of its new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd' .

• Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting

  5/31/2022

  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, held its annual general and special meeting (the "Meeting") of its holders of common shares (the "Shareholders") virtually on May 30, 2022.

• Tetra Bio-Pharma Appoints Chief Financial Officer - May 30, 2022

  5/30/2022

  Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development is pleased to announce the appointment of Leslie Auld, H.BSc, MBA, CPA, as Chief Financial Officer and member of the Company's executive team, effective May 30, 2022.

• Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology

  5/10/2022

  Panag Pharma Inc (Panag), a subsidiary of Tetra Bio-Pharma, will collect royalties on sales on products produced with the technology True North has licensed from Panag.

• Tetra Bio-Pharma's QIXLEEF on Track After Type C Meeting with U.S. FDA

  3/17/2022

  Tetra Bio-Pharma Inc. received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for its inhaled cannabinoid-based product, QIXLEEF™.

• 

  Tetra's Opioid Pain Alternative Moving Closer to FDA Approval

  3/17/2022

  Tetra Bio-Pharma announced that its investigational new drug involving cannabinoids, QIXLEEF, received guidance to strengthen its nonclinical and toxicological data from the FDA.

• Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD

  3/8/2022

  Health Canada approved the amendment of the phase I study to assess the effect of low and moderate doses of inhaled CBD in healthy cannabinoid users.

• Tetra Bio-Pharma Receives $4.5M from the Ministere de l'Economie et de l'Innovation/Investissement Quebec

  2/16/2022

  Tetra Bio-Pharma Inc. is proud to announce the approval of a $4.5M CDN participative loan from the ministère de l'Économie et de l'Innovation (MEI) under the BioMed Propulsion Program, managed by Investissement Québec (IQ).

• Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna

  2/14/2022

  Tetra Bio-Pharma Inc. announced today that it has executed a non-binding term sheet with Avicanna Inc.